Síndrome de Sagliker: una nueva entidad, un problema antiguo.

Abstract

Introduction: Sagliker syndrome, described by Dr. Yahya Sagliker in 2004, constitutes the most advanced state of secondary hyperparathyroidism in chronic kidney disease. Deforming and disabling clinical syndrome that reduces the quality of life and adds psychological disorders to the patient with chronic kidney disease. This study aims to report on a series of eight cases in Mexico and warn about the correct management and follow-up of secondary hyperparathyroidism. Cases: 8 cases are presented with ages between 17 and 35 years, serum parathyroid hormone levels between 1583 and 4715 pg/ml, and alkaline phosphatase levels between 146 and 2065 IU/L. All cases with brown tumors in the maxilla and mandible characteristic of Sagliker syndrome. Evolution: All patients were ingesting calcium and vitamin D analogs at diagnosis or in the last three months. Conclusion: Sagliker syndrome is the most severe and chronic complication of secondary hyperparathyroidism and chronic kidney disease. The significant bone involvement of this syndrome generates a disabling facial and prolonged bone deformity that impacts morbidity, mortality, and mental health. Concomitant with bone alterations, vascular and cardiac calcifications add a crucial cardiovascular risk, so any surgery constitutes a high risk.